BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9329579)

  • 1. Serum S-100 has prognostic significance in malignant melanoma.
    Bonfrer JM; Korse CM; Israels SP
    Anticancer Res; 1997; 17(4B):2975-7. PubMed ID: 9329579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of neuron specific enolase and S100 protein in evaluation of brain damage in patients resuscitated from cardiac arrest].
    Miao WL; Li HL; Wang HD; Wang J; Liu H; Ren HX; Lin HY
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Dec; 19(12):749-52. PubMed ID: 18093437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study.
    Vos MJ; Postma TJ; Martens F; Uitdehaag BM; Blankenstein MA; Vandertop WP; Slotman BJ; Heimans JJ
    Anticancer Res; 2004; 24(4):2511-4. PubMed ID: 15330206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
    Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
    Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of serum S100 in metastatic malignant melanoma.
    Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
    Eur J Cancer; 1995 Jun; 31A(6):924-8. PubMed ID: 7646923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
    Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
    Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of serum S100 in metastatic malignant melanoma.
    Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
    Eur J Cancer; 1995 Oct; 31A(11):1898-902. PubMed ID: 8541129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma.
    Hansson LO; von Schoultz E; Djureen E; Hansson J; Nilsson B; Ringborg U
    Anticancer Res; 1997; 17(4B):3071-3. PubMed ID: 9329604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S-100beta and MIA in advanced melanoma in relation to prognostic factors.
    Auge JM; Molina R; Filella X; Bosch E; Gonzalez Cao M; Puig S; Malvehy J; Castel T; Ballesta AM
    Anticancer Res; 2005; 25(3A):1779-82. PubMed ID: 16033099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma.
    Smit LH; Nieweg OE; Mooi WJ; Bonfrer JM; Haanen JB; Kroon BB; De Gast GC
    Anticancer Res; 2008; 28(4C):2297-302. PubMed ID: 18751409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma.
    Bolander A; Agnarsdóttir M; Wagenius G; Strömberg S; Pontén F; Ekman S; Brattström D; Larsson A; Einarsson R; Ullenhag G; Hesselius P; Bergqvist M
    Melanoma Res; 2008 Dec; 18(6):412-9. PubMed ID: 19011512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
    Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
    Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-100 and NSE as serum markers in melanoma.
    Tofani A; Cioffi RP; Sciuto R; Rea S; Festa A; Di Filippo F; Cavaliere R; Maini CL
    Acta Oncol; 1997; 36(7):761-4. PubMed ID: 9490097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of serum S-100 protein and 5-S-cysteinyl-DOPA levels in melanoma patients].
    Bánfalvi T; Bezzegh A; Edesné BM; Fejös Z; Liszkay G; Schumann B; Kremmer T; Ottó S; Gilde K
    Orv Hetil; 1999 Mar; 140(11):599-602. PubMed ID: 10379169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical values of detection of serum levels of S100B and NSE in diagnosis of brain injuries at early period after cardiopulmonary bypass].
    Gu XH; Zhang G; Zhang XQ; Song Y; Wang T; Li SX
    Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(14):975-7. PubMed ID: 17650423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentration of NSE and S-100b during LVAD in non-resuscitated patients.
    Pfeifer R; Ferrari M; Börner A; Deufel T; Figulla HR
    Resuscitation; 2008 Oct; 79(1):46-53. PubMed ID: 18617311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.
    Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E
    Melanoma Res; 2000 Jun; 10(3):237-41. PubMed ID: 10890377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
    Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
    J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum S-100B protein and neuron-specific enolase after traumatic brain injury].
    Sawauchi S; Taya K; Murakami S; Ishi T; Ohtsuka T; Kato N; Kaku S; Tanaka T; Morooka S; Yuhki K; Urashima M; Abe T
    No Shinkei Geka; 2005 Nov; 33(11):1073-80. PubMed ID: 16277220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.